Yong-xiang Xia
Key Laboratory Of Liver Transplantation, NHC Key Laboratory Of Living Donor Liver Transplantation
Nanjing, China
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
CRISPR/Cas9 screen identifies DCAF4 as a novel protector of hepatocellular carcinoma against brachytherapy via stress granule-dependent NRF2 activation.
Journal: Cell death & disease
Published: January 28, 2026
Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: September 27, 2025
Radiogenomics predicts immune microenvironment heterogeneity and response to combination immunotherapy in hepatocellular carcinoma.
Journal: Journal of translational medicine
Published: March 01, 2025
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study.
Journal: Hepatobiliary & pancreatic diseases international : HBPD INT
Published: December 05, 2024
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target.
Journal: Clinical and molecular hepatology
Published: October 09, 2024
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: October 31, 2023
miR-455/GREM1 axis promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing M2 macrophage polarization.
Journal: Cancer cell international
Published: August 06, 2023
Differentiation and immunosuppressive function of CD19+CD24hiCD27+ regulatory B cells are regulated through the miR-29a-3p/NFAT5 pathway.
Journal: Hepatobiliary & pancreatic diseases international : HBPD INT
Published: May 27, 2023
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: March 23, 2023
Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma.
Journal: Cancer cell international
Published: February 13, 2023
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.
Journal: Journal for immunotherapy of cancer
Published: January 13, 2023
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2022
Last Updated: 09/26/2026